SG11202007977RA - Ophthalmic composition comprising diquafosol and cationic polymer - Google Patents

Ophthalmic composition comprising diquafosol and cationic polymer

Info

Publication number
SG11202007977RA
SG11202007977RA SG11202007977RA SG11202007977RA SG11202007977RA SG 11202007977R A SG11202007977R A SG 11202007977RA SG 11202007977R A SG11202007977R A SG 11202007977RA SG 11202007977R A SG11202007977R A SG 11202007977RA SG 11202007977R A SG11202007977R A SG 11202007977RA
Authority
SG
Singapore
Prior art keywords
diquafosol
cationic polymer
ophthalmic composition
ophthalmic
composition
Prior art date
Application number
SG11202007977RA
Inventor
Kyohei Takahashi
Hiroyuki Asada
Asuka Kamimura
Kenji Morishima
Yusuke Momokawa
Kenichi Endo
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11202007977RA publication Critical patent/SG11202007977RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SG11202007977RA 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer SG11202007977RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (en) 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer

Publications (1)

Publication Number Publication Date
SG11202007977RA true SG11202007977RA (en) 2020-09-29

Family

ID=67806273

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007977RA SG11202007977RA (en) 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer

Country Status (13)

Country Link
US (1) US20210000844A1 (en)
EP (1) EP3760207A4 (en)
JP (4) JP6716800B2 (en)
KR (2) KR20220163519A (en)
CN (2) CN117137866A (en)
BR (1) BR112020017661A2 (en)
CA (1) CA3091700A1 (en)
EA (1) EA202092030A1 (en)
MX (2) MX2020008925A (en)
PH (1) PH12020551313A1 (en)
SG (1) SG11202007977RA (en)
TW (2) TWI781296B (en)
WO (1) WO2019168023A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220163519A (en) 2018-02-28 2022-12-09 산텐 세이야꾸 가부시키가이샤 Ophthalmic composition comprising diquafosol and cationic polymer
WO2020175525A1 (en) * 2019-02-27 2020-09-03 参天製薬株式会社 Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer
KR20240049646A (en) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 Diquafosol or salt thereof, and aqueous ophthalmic composition containing polyvinylpyrrolidone
JP7230169B2 (en) * 2020-12-25 2023-02-28 参天製薬株式会社 Aqueous ophthalmic solution containing diquafosol or its salt, silver salt and ionic tonicity agent
CN113712910A (en) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 Eye drops and preparation method thereof
KR20230143117A (en) 2022-04-04 2023-10-11 서울대학교산학협력단 Compositions for inhibiting sweetness and methods for inhibiting sweetness in foods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (en) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd Aqueous liquid preparation and production thereof
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (en) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 Anti-inflammatory eye drops
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
PT1012154E (en) 1997-07-25 2004-08-31 Inspire Pharmaceuticals Inc METHOD FOR PREPARING THE METHOD FOR PREPARATION, AND THEIR UTILIZATIONS
KR100832821B1 (en) * 2000-05-30 2008-05-28 산텐 세이야꾸 가부시키가이샤 Ectocornea extension promoters
SG177132A1 (en) * 2005-02-14 2012-01-30 Johnson & Johnson Vision Care A comfortable ophthalmic device and methods of its production
JP4515960B2 (en) 2005-05-19 2010-08-04 株式会社資生堂 Hairdressing detergent and method for using the same
KR100870104B1 (en) * 2005-11-28 2008-11-26 주식회사 머젠스 Composition Having Effect on Treatment and Prevention of Dry eye syndrome
JP5421272B2 (en) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド Compositions and methods for the treatment of eye diseases
US20110003816A1 (en) * 2008-03-07 2011-01-06 Sun Pharma Advanced Research Company Limited Ophthalmic composition
SG10201508591UA (en) * 2010-12-28 2015-11-27 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
MX353874B (en) * 2012-03-26 2018-02-01 Santen Pharmaceutical Co Ltd Diquafosol-containing eye drop.
WO2015169728A1 (en) * 2014-05-07 2015-11-12 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
CN106456791B (en) * 2014-06-10 2021-08-10 日本乐敦制药株式会社 Ophthalmic aqueous composition
SG11201705138QA (en) * 2014-12-25 2017-07-28 Santen Pharmaceutical Co Ltd Aqueous ophthalmic solution
KR101587385B1 (en) 2015-07-29 2016-01-21 국제약품공업주식회사 Non-irritating cyclosporin ophthalmic solution and convenient manufacturing process
TW201722419A (en) * 2015-08-24 2017-07-01 參天製藥股份有限公司 Ophthalmic film formulation
JP6192130B2 (en) 2015-12-09 2017-09-06 株式会社大一商会 Game machine
EP3266446B1 (en) * 2016-07-07 2018-11-21 Laboratorios SALVAT, S.A. Ophthalmic composition comprising castor oil and medium chain triglyceride
CN106772747B (en) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 Optical film and manufacturing method thereof
JP6582029B2 (en) * 2017-10-03 2019-09-25 株式会社メニコン Ophthalmic composition liquid and method of use thereof
KR20220163519A (en) 2018-02-28 2022-12-09 산텐 세이야꾸 가부시키가이샤 Ophthalmic composition comprising diquafosol and cationic polymer
CN108853016A (en) * 2018-09-26 2018-11-23 广州大光制药有限公司 A kind of ophthalmic solution sodium eye drops and preparation method thereof
WO2020175525A1 (en) * 2019-02-27 2020-09-03 参天製薬株式会社 Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer

Also Published As

Publication number Publication date
US20210000844A1 (en) 2021-01-07
TWI781296B (en) 2022-10-21
PH12020551313A1 (en) 2021-09-06
CA3091700A1 (en) 2019-09-06
KR20220163519A (en) 2022-12-09
EA202092030A1 (en) 2020-11-16
MX2022014791A (en) 2023-01-16
BR112020017661A2 (en) 2020-12-22
EP3760207A4 (en) 2023-10-04
CN111757742A (en) 2020-10-09
JP6716800B2 (en) 2020-07-01
KR20200127002A (en) 2020-11-09
MX2020008925A (en) 2020-10-01
JP7472202B2 (en) 2024-04-22
KR102472773B1 (en) 2022-11-30
CN111757742B (en) 2023-09-26
EP3760207A1 (en) 2021-01-06
TWI833406B (en) 2024-02-21
TW202306572A (en) 2023-02-16
CN117137866A (en) 2023-12-01
WO2019168023A1 (en) 2019-09-06
JP2022136152A (en) 2022-09-15
JP2024045506A (en) 2024-04-02
JP7297718B2 (en) 2023-06-26
TW202000212A (en) 2020-01-01
JP2020138980A (en) 2020-09-03
JPWO2019168023A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
SG11202007977RA (en) Ophthalmic composition comprising diquafosol and cationic polymer
IL260925A (en) Dendrimer-bioadhesive polymer hydrogel nanoglue and use thereof
IL263419A (en) Biocompatible zwitterionic polymer coatings and hydrogels for reducing foreign body response and fibrosis
IL274718A (en) Ophthalmic composition and delivery device thereof
EP3517577A4 (en) Curing reactive silicone gel and use thereof
EP3981393A4 (en) Biomimetic tissue-adhesive hydrogel patch and use thereof
GB201704211D0 (en) Ophthalmic delivery device and ophthalmic drug compositions
GB2562172B (en) Functionalised polyalkyleneimine polymer and use thereof
IL276918A (en) Ophthalmic formulation
PL3452075T3 (en) Ophthalmic pharmaceutical composition
EP3272811A4 (en) Silicone rubber composition and vulcanized object
GB202202470D0 (en) Bio-ink formulations, bio-printed corneal lenticule, and applications thereof
IL267991A (en) Zwitterionically modified polymers and hydrogels
EP3266803A4 (en) Polymer and crosslinked body thereof
FI3638251T3 (en) Bisphosphocin gel formulations and uses thereof
EP3400972A4 (en) Gel material for ophthalmic treatment use
IL278209A (en) Cationic polymer and use for biomolecule delivery
EP3618882A4 (en) Biocompatible hydrogel compositions and uses thereof
EP3711782A4 (en) Hydrocolloid composition and biopatch comprising same
ZA202203618B (en) Mmup monomer variant and application thereof
EP3721890A4 (en) Ophthalmic drug preparation and uses thereof
IL279446A (en) Hydrogel composition comprising a crosslinked polymer
SG11202007077YA (en) An ophthalmic pharmaceutical composition and its preparation methods and applications
EP3685828A4 (en) Ophthalmic pharmaceutical composition, ophthalmic kit, and pharmaceutical application thereof
ZA202203568B (en) Mnep monomer variant and application thereof